מדיקינט MR כמוסות בשחרור מושהה 20 מ"ג ישראל - עברית - Ministry of Health

מדיקינט mr כמוסות בשחרור מושהה 20 מ"ג

mediline ltd. - methylphenidate hydrochloride 20 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

מודיקיט MR כמוסות בשחרור מושהה 30 מ"ג ישראל - עברית - Ministry of Health

מודיקיט mr כמוסות בשחרור מושהה 30 מ"ג

mediline ltd. - methylphenidate hydrochloride 30 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient.treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

מדיקינט MR כמוסות בשחרור מושהה 40 מ"ג ישראל - עברית - Ministry of Health

מדיקינט mr כמוסות בשחרור מושהה 40 מ"ג

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

אומניק 0.4 ישראל - עברית - Ministry of Health

אומניק 0.4

cts ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - treatment of functional symptoms of benign prostatic hyperplasia (bph).

טמסולין ישראל - עברית - Ministry of Health

טמסולין

rafa laboratories ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

טמסולין ישראל - עברית - Ministry of Health

טמסולין

rafa laboratories ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

טמסולוסין מרק 0.4 מ"ג ישראל - עברית - Ministry of Health

טמסולוסין מרק 0.4 מ"ג

genmedix - tamsulosin hydrochloride 0.4 mg - modified release capsules - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

ריטלין LA ® 40 מ"ג כמוסות בשחרור מושהה ישראל - עברית - Ministry of Health

ריטלין la ® 40 מ"ג כמוסות בשחרור מושהה

novartis pharma services ag - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

ריטלין ® LA כמוסות בשחרור מושהה 10 מ"ג ישראל - עברית - Ministry of Health

ריטלין ® la כמוסות בשחרור מושהה 10 מ"ג

novartis pharma services ag - methylphenidate hydrochloride 10 mg - modified release capsules - methylphenidate - attention deficit hyperactivity disorder (adhd) .

וימובו ישראל - עברית - Ministry of Health

וימובו

astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers.vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.